In a world obsessed with digital footprints, Neovasc is the ultimate paradox: a company with $385M in funding and $21.8M in revenue that generates absolutely zero detectable web traffic. This isn't a startup failure—it's a strategic fortress that reveals the harsh divide between consumer hype and B2B medical reality.

"Neovasc proves that in medical device investing, web traffic is vanity, FDA approval is sanity, and revenue is the only reality that matters."

The executive team reveals the company's true focus: Bill Little leads Corporate Development and Strategy, Tomas Clinton handles Biocompatibility Science, and Rory Moloney manages R&D Packaging. This isn't a company hiring growth hackers—they're hiring scientists and regulatory experts. The absence of a Chief Marketing Officer or Head of Growth speaks volumes about their go-to-market strategy: it's not about acquiring customers; it's about getting medical devices through FDA approval and into operating rooms.

• Zero web traffic indicates a pure B2B medical device model with no direct-to-consumer component
• The $385M funding vs $21.8M revenue suggests a company in late-stage clinical trials awaiting approval
• 87 employees is a lean team for a company with this much capital—likely focused on R&D and regulatory affairs
• The executive team is heavy on science and strategy, light on marketing and sales